CD40 Agonists Alter the Pancreatic Cancer Microenvironment by Shifting the Macrophage Phenotype toward M1 and Suppress Human Pancreatic Cancer in Organotypic Slice Cultures
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: CD40 agonists are thought to generate antitumor effects on pancreatic cancer via macrophages and T cells. We aimed to investigate the role of CD40 agonists in the differentiation of macrophages and treatment of human pancreatic adenocarcinoma. Methods: Immunohistochemistry was performed on paraffin-embedded surgical blocks from patients with pancreatic cancers to evaluate macrophage phenotypes and their relationship with survival. The effects of CD40 agonists on macrophage phenotypes and human pancreatic cancer were evaluated utilizing cell cocultures and organotypic slice cultures. Results: CD163+ (predominant in M2 macrophages) and FOXP3+ (predominant in regulatory T cells) expression levels in the tumors were significantly lower in patients with stage IB pancreatic cancer than in those with stage II or III disease (p=0.002 and p=0.003, respectively). Patients with high CD163+ expression had shorter overall survival than those with low CD163+ expression (p=0.002). In vitro treatment of THP-1 macrophages with a CD40 agonist led to an increase in HLA-DR+ (predominant in M1 macrophages) and a decrease in CD163+ expression in THP-1 cells. Cell cocultures showed that CD40 agonists facilitate the suppression of PANC-1 human pancreatic cancer cells by THP-1 macrophages. Organotypic slice cultures showed that CD40 agonists alter the pancreatic cancer microenvironment by shifting the macrophage phenotype toward M1 (increase HLA-DR+ and decrease CD163+ expression), decreasing the abundance of regulatory T cells, and increasing tumor cell apoptosis. Conclusions: CD163 is related to advanced human pancreatic cancer stages and shorter overall survival. CD40 agonists alter macrophage phenotype polarization to favor the M1 phenotype and suppress human pancreatic cancer.
Abstract
Background/Aims: CD40 agonists are thought to generate antitumor effects on pancreatic cancer via macrophages and T cells. We aimed to investigate the role of CD40 agonists in the differentiation of macrophages and treatment of human pancreatic adenocarcinoma. Methods: Immunohistochemistry was performed on paraffin-embedded surgical blocks from patients with pancreatic cancers to evaluate macrophage phenotypes and their relationship with survival. The effects of CD40 agonists on macrophage phenotypes and human pancreatic cancer were evaluated utilizing cell cocultures and organotypic slice cultures. Results: CD163+ (predominant in M2 macrophages) and FOXP3+ (predominant in regulatory T cells) expression levels in the tumors were significantly lower in patients with stage IB pancreatic cancer than in those with stage II or III disease (p=0.002 and p=0.003, respectively). Patients with high CD163+ expression had shorter overall survival than those with low CD163+ expression (p=0.002). In vitro treatment of THP-1 macrophages with a CD40 agonist led to an increase in HLA-DR+ (predominant in M1 macrophages) and a decrease in CD163+ expression in THP-1 cells. Cell cocultures showed that CD40 agonists facilitate the suppression of PANC-1 human pancreatic cancer cells by THP-1 macrophages. Organotypic slice cultures showed that CD40 agonists alter the pancreatic cancer microenvironment by shifting the macrophage phenotype toward M1 (increase HLA-DR+ and decrease CD163+ expression), decreasing the abundance of regulatory T cells, and increasing tumor cell apoptosis. Conclusions: CD163 is related to advanced human pancreatic cancer stages and shorter overall survival. CD40 agonists alter macrophage phenotype polarization to favor the M1 phenotype and suppress human pancreatic cancer.
참고문헌 (37)
- Helm O, "Tumorassociated macrophages exhibit pro-and anti-inflammatory properties by which they impact on pancreatic tumorigenesis", Int J Cancer, 135, pp.843~861 (2014)
- Sica A, "Macrophage polarization in tumour progression", Semin Cancer Biol, 18, pp.349~355 (2008)
- Hasita H, "Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma", Cancer Sci, 101, pp.1913~1919 (2010)
- Minami K, "Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma", Exp Ther Med, 15, pp.4465~4476 (2018)
- Ino Y, "Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer", Br J Cancer, 108, pp.914~923 (2013)
- Liu CY, "M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4", IL-10 signaling pathway, 2013, pp.93, 844~854
- Zhu Y, "Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression", Immunity, 47, pp.323~338 (2017)
- Vonderheide RH, "CD40 immunotherapy for pancreatic cancer", Cancer Immunol Immunother, 62, pp.949~954 (2013)
- Schoenberger SP, "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions", Nature, 393, pp.480~483 (1998)
- Beatty GL, "CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans", Science, 331, pp.1612~1616 (2011)
- Byrne KT, "CD40 stimulation obviates innate sensors and drives T cell immunity in cancer", Cell Rep, 15, pp.2719~2732 (2016)
- O’Sullivan T, "Cancer immunoediting by the innate immune system in the absence of adaptive immunity", J Exp Med, 209, pp.1869~1882 (2012)
- Rakhmilevich AL, "CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors", Cancer Immunol Immunother, 57, pp.1151~1160 (2008)
- Buhtoiarov IN, "CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro", J Immunol, 174, pp.6013~6022 (2005)
- Lim CY, "Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response", Pancreatology, 18, pp.913~927 (2018)
- Lankadasari MB, "TAMing pancreatic cancer : combat with a double edged sword", Mol Cancer, 18, pp.48~ (2019)
- Ainhoa Mielgo, "Impact of tumour associated macrophages in pancreatic cancer", BMB Reports, 46(3), pp.131~138 (2013), 생화학분자생물학회
- Sica A, "Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression : potential targets of anticancer therapy", Eur J Cancer, 42, pp.717~727 (2006)
- Yang J, "Macrophages in pancreatic cancer : an immunometabolic perspective", Cancer Lett, 498, pp.188~200 (2021)
- Chen SJ, "Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8", Cancer Med, 7, pp.5679~5690 (2018)
- Kurahara H, "Significance of M2-polarized tumor-associated macrophage in pancreatic cancer", J Surg Res, 167, pp.e211~e219 (2011)
- Hu H, "The M2phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer", Tumour Biol, 37, pp.8657~8664 (2016)
- Miura T, "Prognostic impact of CD163+ macrophages in tumor stroma and CD8+ T-cells in cancer cell nests in invasive extrahepatic bile duct cancer", Anticancer Res, 37, pp.183~190 (2017)
- Sanford DE, "Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer : a role for targeting the CCL2", CCR2 axis, 2013, pp.19, 3404~3415
- Zhu Y, "CSF1", CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models, 2014, pp.74, 5057~5069
- Li M, "Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1", CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy, 2020, pp.321, 23~35
- Rosati A, "BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages", Nat Commun, 6, pp.8695~ (2015)
- Luheshi NM, "Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1blockade in a mouse orthotopic pancreatic tumour model", Oncotarget, 7, pp.18508~18520 (2016)
- Ma HS, "A CD40 agonist and PD-1antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity", Cancer Immunol Res, 7, pp.428~442 (2019)
- Gerlach MM, "Slice cultures from head and neck squamous cell carcinoma : a novel test system for drug susceptibility and mechanisms of resistance", Br J Cancer, 110, pp.479~488 (2014)
- Koerfer J, "Organotypic slice cultures of human gastric and esophagogastric junction cancer", Cancer Med, 5, pp.1444~1453 (2016)
- Naipal KA, "Tumor slice culture system to assess drug response of primary breast cancer", BMC Cancer, 16, pp.78~ (2016)
- Jiang X, "Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment", Oncoimmunology, 6, pp.e1333210~ (2017)
- Misra S, "Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma", Sci Rep, 9, pp.2133~ (2019)
- Seo YD, "Mobilization of CD8+ T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer", Clin Cancer Res, 25, pp.3934~3945 (2019)
- Jayasingam SD, "Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue : technicalities and challenges in routine clinical practice", Front Oncol, 9, pp.1512~ (2020)
- Hu JM, "CD163 as a marker of M2 macrophage, contribute to predicte aggressiveness and prognosis of Kazakh esophageal squamous cell carcinoma", Oncotarget, 8, pp.21526~21538 (2017)